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Abstract
There is increasing evidence for the "cancer stem cell (CSC) hypothesis", which holds that cancers
are driven by a cellular component that has stem cell properties, including self-renewal,
tumorigenicity and multi-lineage differentiation capacity. Researchers and oncologists see in this
model an explanation as to why cancer may be so difficult to cure, as well as a promising ground
for novel therapeutic strategies. Given the specific stem cell features of self-renewal and
differentiation, which drive tumorigenesis and contribute to cellular heterogeneity, each marker
and assay designed to isolate and characterize CSCs has to be functionally validated. In this review,
we survey tools and markers available or promising to identify breast CSCs. We review the main
models used to study breast CSCs and how they challenge the CSC hypothesis.
Background
Understanding the role of CSCs during carcinogenesis,
from tumor initiation to metastasis formation, has
become a major focus in stem cell biology and in cancer
research. Considerable efforts are directed towards devel-
oping clinical applications of the CSC concept. However,
it is crucial to functionally validate each marker and
model utilized to isolate and characterized CSC. In this
review, we give an overview of the tools available to study
breast CSCs and describe their implications to improve
breast cancer treatment. The cancer stem cell (CSC) model
holds that tumors are organized in a cellular hierarchy in
which CSCs are the only cells with unlimited proliferation
potential and with the capability of driving tumor growth
and progression. According to this model, cancers origi-
nate from the malignant transformation of an adult stem
cell or progenitor through the disregulation of the nor-
mally tightly regulated self-renewal program. This leads to
clonal expansion of stem/progenitor cells that undergo
further genetic or epigenetic alterations to become fully
transformed. As a consequence of this, tumors contain a
cellular component of CSCs which retain the key stem cell
properties that initiate and drive carcinogenesis.
A major goal of both researchers and oncologists is to
understand how many and which tumor cells must be
eliminated for a given treatment to succeed. Eliminating
cancer cells that have limited proliferation potential,
while sparing cancer stem cells that have unlimited prolif-
eration potential will eventually result in relapse or recur-
rence. This hypothesis has been recently validated by
different studies that described CSCs from various tissues
as a cell population resistant to current anticancer thera-
pies, antimitotic agents and radiation [1-6].
Some years ago, a subset of cells from a neuroblastoma
cell line identified upon their capacity to exclude vital dye
as a Side Population (SP cells) showed the ability to resist
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chemotherapy. Although SP and non-SP cells were able to
proliferate in the absence of antimitotic agents, SP cells
could proliferate as colonies in the presence of mitox-
antrone, while non-SP cells could not. These data sug-
gested that a subpopulation of neuroblastoma cells
shared some properties with stem cells and were selected
in vitro by chemotherapy [7].
In breast tumors, the use of neoadjuvant regimens
showed that conventional chemotherapy could lead to
enrichment in CSCs in treated patients as well as in
xenografted mice [1,3]. Furthermore, primary mammos-
pheres from chemotherapy-treated patients showed simi-
lar mammosphere-initiating capacity after eight to ten
generations, whereas cells from untreated patients van-
ished within two to three generations, suggesting again an
increase in cells with self-renewal potential after chemo-
therapy [3]. The radiation effect on CSCs was studied in
vitro, using staining of phosphorylated histone H2AX and
the measurement of reactive oxygen species as functional
tests for radiation resistance [2]. In MCF7, CSC/progeni-
tors isolated as mammospheres were more resistant to
radiotherapy than cells in monolayer culture, and frac-
tionated radiotherapy increased the proportion of breast
CSCs with the CD44+/CD24-/low phenotype [2].
These data reinforce the belief that CSCs resist many cur-
rent therapies and that they are the actual targets to elim-
inate if treatment is to be curative. Interestingly, treatment
of ERBB2-positive tumors with the EGFR/ERBB2 inhibitor
lapatinib led to a small decrease in the percentage of
breast CSCs [1]. Thus, appropriate targeted therapies can
eliminate CSCs.
The success of our efforts in translating cancer stem cell
research into clinical practice depends on how thorough
and rigorous we are at characterizing these cells. It also
relies on how practical and reliable are the markers and
assays designed to study CSCs.
Techniques for the characterization of cancer 
stem cells
Side population technique
The SP technique has been used for many years to isolate
both normal and tumor stem cells from different organs
and species [7-10]. It is based on the abilities of stem cells
to exclude vital dyes. Normal and cancer stem cells express
transmembrane transporters, such as the ATP-binding cas-
sette protein, ABC transporter ABCG2/BCRP1 (breast can-
cer resistance protein 1). These molecules exclude dyes
such as Hoechst 33342 or Rhodamin 123 from the cells, a
property not found in differentiated cells that remain pos-
itive for the dye.
SP cells isolated from reduction mammoplasty of normal
breast in volunteer healthy women, were found to express
more BCRP1 than non-SP cells. Moreover, a specific
BCRP1 inhibitor (Ko143) reduced SP formation, suggest-
ing that BCRP1 confers the SP phenotype in mammary
epithelial cells. Interestingly, SP cells did not express
either luminal or myoepithelial markers (EMA and
CALLA/CD10) or estrogen receptor (ER), whereas non-SP
cells did [11]. A relatively undifferentiated phenotype
without any luminal marker expression was also dis-
played by cells from mammospheres, obtained after non-
adherent serum-free culture of normal mammary gland,
and proven to be enriched in stem/progenitors cells [12].
The SP fraction from uncultured mammary cells repre-
sented ~1% of cells. In contrast, in mammospheres, the SP
fraction represented 27% of the cells and could generate
bi-lineage colonies when cultured under differentiating
conditions, suggesting that the SP fraction contained the
bipotent progenitors and was capable of mammosphere
formation [12].
In the mouse, SP cells have been shown to regenerate the
gland upon transplantation [13] and to express genes
encoding putative stem cell markers such as α6-integrin
and telomerase [14]. A SP isolated from the breast cancer
cell line MCF7 was found to represent 2% of the total cell
line. It contained the tumorigenic fraction from MCF7, as
demonstrated by transplantation experiments in NOD/
SCID mice xenografts. This fraction was also able to recon-
stitute the initial heterogeneity of the cell line [15,16].
The SP technique for CSCs has also been successfully used
in other species and tissues [7-10,17]. However, func-
tional studies using Hoechst staining are limited by the
toxicity of this agent. Consequently, if Hoechst-positive
cells do not grow in vivo or in vitro, the reason could be a
direct toxic effect of the dye, shedding doubts on the reli-
ability of the experiments. Furthermore, evidence from
mouse models indicates that the mammary repopulating
units with functional stem cell activity are not contained
within the SP [9,18]. This is mainly why the SP technique
is no longer the preferred approach for stem cell studies.
Expression of cell surface markers
Expression of cell surface markers has been widely used to
isolate stem cells, but the choice of marker can greatly vary
depending on tissues or species. The following markers
have been used in the study of breast stem cells:
-CD44+/CD24-//low lin-
The pioneering study by Clarke and colleagues used breast
cancer xenografts to isolate a population of cells able to
initiate tumors in NOD/SCID mice [19]. This population
was defined by the combined expression of cell surface
markers CD44+/CD24-/low/lin-. As few as 200 of these cellsBMC Cancer 2009, 9:202 http://www.biomedcentral.com/1471-2407/9/202
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generated tumors in NOD/SCID mice whereas 20,000
cells that did not display this phenotype failed to do so.
The NOD/SCID tumors recapitulated the entire heteroge-
neity of the initial tumor. Furthermore, the CD44+/CD24-
/low/lin- cell population was able to reinitiate tumors in
NOD/SCID mice, and retained this ability after serial pas-
sages. Thus, these cells, which were able to self-renew, to
differentiate, and displayed tumorigenic capacity, had
CSC features.
The CD44high/CD24low phenotype has been used to iso-
late stem cells from the human normal mammary epithe-
lium. This phenotype seems to be conserved during the
carcinogenesis process and thus is an important tool to
study breast cancer progression, however, it is limited by
the great cellular heterogeneity of the CD44+/CD24-/low/
lin-population, which probably does not contain solely
bona fide CSCs. The use of the CD44+/CD24-/low/lin- phe-
notype and another marker, the ALDEFLUOR assay,
which measures the Aldehyde dehydrogenase enzymatic
activity, demonstrated that cells able to initiate tumor in
mice were within the ALDEFLUOR-positive cells, the cells
displaying both phenotypes being the most tumorigenic,
and that none of the CD44+/CD24-/low/lin- cells without
ALDEFLUOR activity could grow in mice [20]. These
results indicate that the CD44+/CD24-/low/lin- population
contains some but not all the CSCs in breast tumors.
Moreover, while CD44 appears to be a common stem cell
marker [21-23], as well as a promising therapeutic target
[24,25], the CD44+/CD24-/low/lin- phenotype is probably
tissue-restricted. Pancreatic cancer cells with stem cell
properties of self-renewal, ability to produce differenti-
ated progeny, and increased expression of the develop-
mental signaling molecule sonic hedgehog, display a
CD44+/CD24+/ESA+ phenotype [26,27].
- CD49f/ITGA6/α6-integrin
A combination of cell surface markers was used to purify
a rare subset of adult mouse mammary stem cells that
were able individually to regenerate an entire mammary
gland within six weeks in vivo. These cells, sorted as CD45-
/Ter119-/CD31-/Sca-1low/CD24med/CD49fhigh, were desig-
nated as mammary repopulating units (MRUs) and
expressed markers associated with basal cells (smooth
muscle actin and keratin 14). They were different from
progenitor cells that represented the mammary colony
forming cells and expressed keratin 8, 18 and 19 tran-
scripts and keratin 6 protein [28].
Interestingly, a recent study described a subpopulation
that overexpressed the α6-integrin in the human breast
luminal cell line MCF7. This population presented cells
capable of growth in anchorage-independent conditions
as spherical organoids. These cells displayed resistance to
pro-apoptotic agents and greater tumorigenicity than the
whole cell line, with as few as 1,000 cells able to form
tumors in immunodeficient mice [29]. Moreover, knock-
down of α6-integrin/ITGA6 caused mammosphere-
derived cells to lose their ability to grow as mammos-
pheres and abrogated their tumorigenicity in mice, prov-
ing that ITGA6 is required for the growth and survival of
this highly tumorigenic subpopulation of cancer cells, and
suggesting that this adhesion molecule is a potential ther-
apeutic target.
- CD133/PROM1/prominin
The difference in cellular hierarchy between estrogen-
receptor (ER)-negative and ER-positive tumors has only
been addressed recently using cleared fat pad transplanta-
tion assay in mouse and flow cytometry analysis [30]. The
mouse mammary epithelium contained three distinct cell
populations: basal/myoepithelial cells, defined by the
CD24low phenotype, and two distinct CD24high luminal
epithelial populations with different prominin-1 expres-
sion. The CD24high/prominin-1+  cells belonged to the
luminal compartment. The majority of stem/progenitor
cell activity in the adult virgin mouse mammary epithe-
lium was found to be located in the basal compartment,
confirming and extending previous observations [30]. In
contrast, the ER-positive luminal compartment contained
little in vivo stem/progenitor cell activity, indicating that
the hormone-sensing and in vivo stem/progenitor activi-
ties of the mammary epithelium are properties of distinct,
separate cell populations.
Such a clearcut distinction has not yet been firmly estab-
lished in the human mammary gland. However, a model
proposes that the steroid receptor-positive population is a
slowly dividing stem cell population whereas the adjacent
proliferative cells represent transient amplifying popula-
tions [31]. Disregulation of normal self-renewal results in
increased symmetrical cell divisions of stem cells, and
could explain the low proliferation rate of steroid recep-
tor-positive cells in both pre-cancerous and cancerous
breast lesions.
CD133 might be a good candidate to explore carcinogen-
esis and estrogen-dependent tumor progression. In cell
lines from mammary tumors Brca1 knockout mice, the
expression of CD133 cells is associated with stem cell
properties as well as CD44+/CD24-/low phenotype [32].
However, the use of prominin has never been as successful
in isolating CSCs from human breast cancer as it has been
in other organs such as brain tumors or colon carcinomas
[33-35]. In any case, testing the efficiency of CD133
expression to isolate CSCs from luminal ER-positive
breast tumors remains an interesting point to explore.BMC Cancer 2009, 9:202 http://www.biomedcentral.com/1471-2407/9/202
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- CD29/β1-integrin and CD61/β3-integrin
CD29 and CD61 are two cell surface proteins that may
play a role in luminal cell fate determination. CD29 dis-
tinguishes two distinct mammary epithelial populations
among immature CD24+ cells, one enriched for luminal
(CD29low/CD24+) and one for mammary stem cells
(CD29high/CD24+)[36]. The luminal CD29low/CD24+
subpopulation can be further subdivided using CD61 into
CD61+ luminal progenitors and CD61- mature luminal
cells [37]. Moreover, in the mouse model of luminal
MMTV-WNT1 tumors, flow cytometry sorting upon
CD61, identified a CSC population highly enriched for
tumorigenic capability compared to CD61-  cells [38].
CD29 and CD61 could therefore be promising targets for
human clinical applications based on data obtained from
normal and tumoral mouse mammary gland studies.
Flow cytometry methods using cell surface markers have
been successfully applied to mice and human samples to
isolate stem cell populations. Markers available for cell
sorting of stem cell populations of the mouse mammary
gland are numerous, the functional assays well validated
and the cellular hierarchy partly established. In contrast,
in the human mammary gland, the markers are scarce, the
assays difficult to standardize, and the actual hierarchy
remains to be defined. Furthermore and curiously, the
markers used in mice to sort specific stem cell populations
are rarely valid in human. This observation emphasizes
the need for other, more "universal" assays.
ALDEFLUOR assay
The ALDEFLUOR assay may fit the universality required
for a stem cell marker to be reliable across species and tis-
sues. It is based on the enzymatic activity of aldehyde
dehydrogenase 1 (ALDH1), a detoxifying enzyme respon-
sible for the oxidation of retinol to retinoic acid. ALDH1
may have a role in early differentiation of stem cells
[6,39]. High ALDH1 activity is associated with several
types of murine and human stem hematopoietic and neu-
ral stem and progenitor cells [40-43]. As few as 10 ALDE-
FLUOR-positive cells isolated from the rat hematopoietic
system are capable of long term repopulation of bone
marrow upon transplantation in sub-lethally irradiated
animals [40]. ALDH1 activity also identified CSCs in mul-
tiple myeloma and leukemia patients with high capability
of engraftment into NOD/SCID mice [43,44]. A recent
study showed that ALDEFLUOR-positive cells isolated
from the mouse brain were capable of self-renewal and
able to generate neurospheres and neuroepithelial stem-
like cells. These cells were capable of differentiation into
multiple cell lineages in vitro, generating neurons and glia
in culture. Furthermore, ALDEFLUOR-positive cells had a
higher capacity to engraft in vivo, upon transplantation in
brain, compared to ALDEFLUOR-negative cells [45].
This method has been recently used with success to isolate
stem and progenitors cells from mammary tissues. ALDE-
FLUOR-positive cells isolated from both normal and
tumoral human breast had phenotypic and functional
characteristics of mammary stem cells. Furthermore, the
ALDEFLUOR-positive population isolated from human
breast tumors contained the CSC population as demon-
strated by the ability of these cells but not of ALDE-
FLUOR-negative cells to generate tumors in NOD/SCID
mice. Serial passages of ALDEFLUOR-positive cells gener-
ated tumors recapitulating the phenotypical diversity of
the initial tumor [20].
However, the ALDEFLUOR assay does have some limita-
tions for the isolation of the most tumorigenic popula-
tion, notably in tumors of different origin. For example,
both ALDEFLUOR (bright) and ALDEFLUOR (low) from
the lung carcinoma cell line H 522 were able to initiate
tumors after inoculation into NOD/SCID mice. Moreo-
ver, tumors generated from ALDEFLUOR (low) cells grew
faster and bigger than the tumors from ALDEFLUOR
(bright) and this remained true among passages. These
results suggest that the ALDEFLUOR-positive population
in lung carcinoma is not stem cell-enriched compared to
the ALDEFLUOR-negative population [46]. Furthermore,
the stem cell population identified using the ALDEFLUOR
assay is probably heterogeneous, and needs to be dis-
sected using additional markers. In breast cancer cell lines,
the ALDEFLUOR-population has been divided by the use
of CD44+, CD24-  and CD133. ALDEFLUOR-positive
CD44+/CD24- and ALDEFLUOR-positive CD44+/CD133+
populations displayed the greatest tumorigenic and meta-
static potential. This is the first time that CSCs obtained
with a given marker are further divided using additional
markers into distinct metastatic or not metastatic subpop-
ulations [47]. In human hematopoietic stem cells, the
ALDEFLUORhigh lin- population has also been separated
in CD133-positive and negative subsets, with the former
showing enhanced repopulating capacity in recipients of
serial, secondary transplants [42].
These data open new fields for functional stem cell studies
with therapeutic applications using marker combinations.
In situ detection
In situ detection of stem cells has the potential to transfer
stem cell quantification to routine clinical practice for
patient treatment and prognosis evaluation. It also allows
the determination of the CSCs' location within the tumor-
either primary or metastatic sites-, and the detection of
stem cells in pre-invasive stages as well as their modifica-
tions during pre-malignant to malignant progression.
Aldehyde dehydrogenase activity has been mostly attrib-
uted to the function of aldehyde dehydrogenase1A1, oneBMC Cancer 2009, 9:202 http://www.biomedcentral.com/1471-2407/9/202
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of the main ALDH cytoplasmic isoform. This enzyme is
highly expressed in stem cells and is thought to regulate
stem cell function [6]. In situ immunostaining of
ALDH1A1 has been measured in formalin-fixed, paraffin-
embedded breast tumors and it identified both normal
and malignant human mammary stem cells; 30% of the
breast tumors analyzed presented a relatively small
ALDH1-positive cell population. The analysis of ALDH1
expression in human breast carcinomas showed that the
expression of this stem/progenitor cell marker is a power-
ful predictor of poor clinical outcome [20].
These data suggest that in situ detection of CSCs using
ALDH1 immunohistochemistry is a valid, simple method
and a powerful prognosis marker. However, the use of
ALDH1A1 to detect stem cells is not free of controversy. In
transgenic mice, ALDH1A1 deficiency did not affect
hematopoiesis and hematopoietic stem cell (HSC) func-
tion, or ALDEFLUOR staining [48]; it is possible that
other isoforms of ALDH, notably cytoplasmic isoforms
such as ALDH1A3 were responsible both for the mainte-
nance of HSC function and the remaining ALDEFLUOR
staining.
Another method used to detect stem cells in situ is double
immunostaining using CD44 and CD24 antibodies and
subsequent quantification of the CD44+/CD24low/- phe-
notype. The prevalence of CD44+/CD24low/- cells in paraf-
fin-embedded tumors was lower than 10% in the majority
of cases, and this phenotype was neither associated with
clinico-pathologic characteristics nor with clinical out-
come [49]. Strikingly, the presence of the CD44+/
CD24low/- tumor cells was inversely associated with lymph
node metastasis (P = 0.019) and tended to be inversely
associated with the stage of the disease (P = 0.068) [50].
Another study on paraffin-embedded breast tumors
revealed that the CD44+/CD24low/- phenotype is most
common in the basal subtype and particularly common
in BRCA1  hereditary tumors, of which 94% contained
CD44+/CD24low/- cells. The CD44+/CD24low/- phenotype
was surprisingly scarce in ERBB2-positive tumors, which
had a predominantly CD24+ status [51]. In bone marrow
specimens of 50 patients with early breast tumors, CD44+/
CD24low/-  phenotype in cytokeratin-positive cells was
detected in 72% of all disseminated tumor cells (DTC)
compared with less than 10% in primary tumors [52]. In
all these studies, if the CD44+/CD24low/-phenotype is
associated with the basal subtype, or appears in DTC as a
first step toward metastasis, there was no correlation with
clinical outcome, whether disease-free, relapse-free,
metastasis-free or overall survival.
Even if the CD44+/CD24low/-  phenotype is a valuable
marker for the isolation of breast CSCs it cannot be used
in clinical settings. As pointed out by Gabriela Dontu in a
recent commentary, the use of these markers raises several
important questions [53]. Is the CD44+/CD24low/- pheno-
type associated with CSCs only in certain breast cancers,
predominantly basal-like or BRCA1? Are cancers that do
not contain cells with this phenotype driven by a different
CSC? If this is the case, do the CSCs not bearing the
CD44+/CD24low/- phenotype have a different origin? Is it
possible that the CD44+/CD24low/-  phenotype is a
dynamic one, i.e. can it be lost and de novo acquired dur-
ing tumor progression, as a result of genetic instability
and epigenetic changes? Thus, a marker valuable to isolate
CSCs may not be applicable in the clinic, demonstrating
all the pitfalls that come with the validation process.
In order to progress in this field, we will need to further
characterize the breast CSC population using validated
methods. Among the different methods utilized to isolate
breast CSCs some are promising but require validation
with a combination of two or more methods to improve
our knowledge on the cells that drive tumor growth and
evolution (Figure 1). To better understand how these cells
sustain the growth and expansion of the tumor, and
because the stem cell component within primary tumors
can be scarce, it is necessary to develop convenient and
valid models/systems for the study of stem cells, with the
final aim of developing therapeutic strategies.
Anchorage-independent cell culture
Cell culture in non-adherent conditions was initially
adapted to normal breast obtained from reduction mam-
moplasty. Human mammary stem and progenitor cells
were able to survive in suspension and produce spherical
colonies (mammospheres) composed of both stem and
progenitor cells. These non-adherent mammospheres
were enriched in early progenitor/stem cells and able to
differentiate along the three mammary epithelial lineages
and to clonally generate complex functional structures in
reconstituted 3D culture systems as well as reconstitute
human normal mammary gland in mice [12]. This system
is now widely used to study underlying mechanisms of
growth under anchorage-independent conditions, and by
extension, to discover pathways implicated in stem/pro-
genitor cells survival.
Hedgehog pathway, BMI1/polycomb and NOTCH signal-
ing have been shown to play a critical role in normal
human mammary development by acting on both stem
cells and progenitor cells, affecting self-renewal and line-
age-specific differentiation [54,55]. Furthermore, aberrant
activation of NOTCH signaling is involved in early breast
tumorigenesis. Increased NOTCH intracellular domain
staining was found associated with tumor recurrence at
five years (P = 0.012) [56]. Confirming aberrant NOTCH
signaling in early stages of the disease, the formation of
mammospheres from primary pre-invasive ductal carci-BMC Cancer 2009, 9:202 http://www.biomedcentral.com/1471-2407/9/202
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noma in situ (DCIS) was reduced when NOTCH signaling
was inhibited using either DAPT, a γ-secretase inhibitor,
or a NOTCH4-neutralizing antibody [56].
The mammosphere assay, based on the unique property
of stem/progenitor cells to survive and grow in serum-free
suspension, was also successfully used to establish long-
term cultures enriched in stem/progenitor cells from inva-
sive tumor samples. The mammospheres formed in these
conditions were called tumorspheres. They showed an
increase in SP fraction and in CD44+/CD24-//low cells,
overexpressed neoangiogenic and cytoprotective factors,
expressed the putative stem cell marker OCT4, and dis-
played high tumorigenic potential in NOD/SCID mice
[57].
Thus, the development of in vitro suspension culture sys-
tems not only provides an important new tool for the
study of mammary cell biology, but also has important
implications for understanding key molecular pathways
in both normal and neoplastic stem cells.
Resources for the characterization of cancer 
stem cells
Breast cell lines
Cell lines have been widely used for decades in the study
of cancer. Since most of the recurrent alterations present
in a primary tumor are retained in the corresponding cell
line, this system has provided invaluable insights into the
role played by deregulated genomic and transcriptional
pathways in mammary oncogenesis [58].
Whether cell lines retain the hierarchical organization of
the primary tumors they derived from is an important
question that has been recently challenged in relation to
cell lines from various origins such as brain glioma, breast
cancer, ovarian cancer, lung cancer, prostate cancer, head
and neck carcinoma, neuroblastoma, and Ewing sarcoma
[7,15,59]. CSCs have also been isolated from different
mouse and human breast cancer cell lines. Recently, a
study reported the isolation of a putative CSC population
in cell lines derived from Brca1Δexon11/P53+/-mouse mam-
mary tumors. This population expressed stem cell markers
(CD44+/CD24-/low or CD133+) and had the ability to grow
Markers and model for breast cancer stem cell studies Figure 1
Markers and model for breast cancer stem cell studies. The main assays, markers and models used to study breast can-
cer stem cells are schematically represented. Models and assays rely on the main stem cells properties that are self-renewal 
ability and differentiation potential. The various markers illustrate the great phenotypic diversity of the cancer stem cell popu-
lation.
ISOLATION
R2 R1
FACS analysis
 CD44+/CD24-/low/lin-
 ALDEFLUOR assay
 Side population
 CD133?
 CD61?
 CD49f/CD29?
MATERIAL
Primary tumor Cell line Mouse xenograft
PROPERTIES
in vitro assay
 Tumorsphere formation
 Serial passages (self-renewal)
in vivo assay
R2 R1
 Tumorigenicity assay
 Recapitulation of the initial phenotype
 Serial passages (self-renewal)BMC Cancer 2009, 9:202 http://www.biomedcentral.com/1471-2407/9/202
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as spheres, to repopulate in vitro the parental cell fractions
after several passages, to resist chemotherapeutic agents,
or to be more tumorigenic than the parental line [32].
A subpopulation of MCF7 was able to grow as spherical
organoids in anchorage-independent conditions, dis-
played resistance to pro-apoptotic agents and greater tum-
origenicity than its parental line in immunodeficient mice
[29]. Several other studies have used putative CSC mark-
ers such as CD44+/CD24-/low to identify similar popula-
tions within breast cancer cell lines, but given that CD44
is a basal marker, this phenotype did not isolate the tum-
origenic population [60]. While these studies represent a
major advance in validating the use of cell lines for stem
cell biology, they lack important key features such as in
vivo validation of self-renewal ability and differentiation,
or are restricted to one or few cell lines.
In a recent study, we used the ALDEFLUOR assay to isolate
and characterize CSCs from 33 breast cell lines, derived
from normal and malignant mammary tissue [61]. 23 of
the cell lines contained an ALDEFLUOR-positive popula-
tion that displayed stem cell properties in vitro and in
NOD/SCID xenografts. Gene expression profiling identi-
fied a 413-gene "cancer stem cell" profile that included
genes known to play a role in stem cell function as well as
genes such as CXCR1/IL8RA not previously reported to
play such a role. Recombinant IL8 increased mammos-
phere formation and the ALDEFLUOR-positive popula-
tion in breast cancer cell lines. We further showed that
ALDEFLUOR-positive cells are responsible for mediating
metastasis. These studies confirm the hierarchical organi-
zation of immortalized cell lines.
The use of cell lines can facilitate the characterization of
regulatory pathways of cancer stem cells and identify
potential stem cell markers and therapeutic targets.
Human xenograft models
Many different pathways are involved in the determina-
tion of stem cell fate. These may be deregulated in cancer
and hence represent potential pathways to target with new
therapeutic strategies. Molecules that target these path-
ways can be first tested in vitro but they need to be subse-
quently validated in vivo in immunodeficient animals.
Despite the caveats represented by a change in the func-
tional properties of CSCs in the animal host and the
changes in the niche (tumoral stroma, hormonal influ-
ence), the xenograft model of patient samples appears to
be the closest experimental system to tumors in human
patients.
Unlike cell line-derived xenografts, tumor xenografts
maintain the cell differentiation and morphology, the
architecture, and molecular signatures of the original
tumors [62]. Vasculature, stroma, central necrosis, and
peripheral growth occur in tumor-bearing mice in a way
that is similar to that of the patient's tumor. Furthermore,
tumor xenografts are the most relevant way to test CSC
properties such as the ability to form tumors, self-renewal
potential and capacity to differentiate. Among the large
variety of tumors transplantable into immunodeficient
mice, breast cancers are among the most difficult to estab-
lish [63].
When introducing tissue fragments or dissociated human
mammary epithelial cells (hMECs) into the cleared
mouse mammary fat pads of immunodeficient mice to
recreate a functional gland, the microenvironment plays
an eminent role [64]. Early attempts were unsuccessful
presumably because of the inadequate stromal environ-
ment of the mouse mammary fat pad. Success came when
normal fibroblasts were introduced in the fat pad of
NOD/SCID mice prior to injection ("humanization").
Human primary mammary cells were able to survive and
colonize the humanized mammary gland [65]. Ortho-
topic injection of epithelial normal or tumoral cells in
cleared and "humanized" fat pad is closer to the human
tumor and more suitable for stem cell studies compared
with subcutaneous injection [20].
However, concerns about the adequacy of immunodefi-
cient mice model for stem cell studies remain. A report has
recently challenged the use of immunodeficient mice to
transplant human cancer cells [66]. In this study, as few as
10 leukemic cells from mice genetically engineered to
develop leukemia were injected into genetically compati-
ble healthy animals. All recipient mice developed leuke-
mia, raising concerns that the experiments do not
accurately reflect cancer initiation and progression in
human patients. Results suggested that the mouse does
not provide the right environment for the growth of
human cancer cells, and questioned the CSC hypothesis.
More recently, it was shown that the frequency of tumor-
initiating cells detected in human melanoma was highly
dependent on the mouse model used for their assessment
[67]. This frequency was as high as one in four cells when
assayed in highly immunodeficient NOD/SCID Il2rg-/-
mice but several orders of magnitude lower in NOD/SCID
mice (that have NK cells). The too high frequency of
tumor-initiating cells questioned the CSC model.
Another interpretation of data suggests that the amount of
tumor-initiating cells is not automatically small but can
vary among tumors. The CSC hypothesis does not rely on
the size of the cancer-initiating population but on the
presence of a hierarchy within the tumors. Moreover, the
use of re-transplantation of marked cell populations
allows for the distinction of self-renewal from prolifera-
tion, a property of many cell types. In contrast, becauseBMC Cancer 2009, 9:202 http://www.biomedcentral.com/1471-2407/9/202
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Quintana et al. did not utilize defined cell populations
[67], the demonstration of self-renewal would require
tumor generation in serial passages of single cells. The
increase in the number of tumor-initiating cells in a more
permissive environment may be an argument in favor of
environment-dependent properties for these cells. Never-
theless, these results highlight the major role of the
stroma/microenvironment in CSC studies, and argue in
favor of the choice of a xenograft model as close as possi-
ble to the native human environment.
Conclusion
The application of the cancer stem cell model to the clinic
implies that the elimination of CSCs is mandatory to cure
cancer. Because normal and tumor stem cells often share
common pathways, the use of drugs that target specific
stem cell pathways is both a powerful strategy and a great
challenge. In this context, it appears more significant than
ever to use reliable tools and systems for stem cell studies.
Different markers have been described to isolate and tar-
get stem cells, but a striking feature is that there is rela-
tively little overlap between the different CSC markers
reported in different tumor types or species (human,
mice).
It is essential to define if and how solid tumors are formed
from a single CSC and to determine whether CSCs are het-
erogeneous and exhibit different degrees of "stemness".
Analysis of patients at different stages of disease, and spe-
cially a follow-up of CSCs during and after treatment or at
the time of relapse will help answer the question of clonal
evolution and is therefore a major goal in order to adapt
treatment accordingly.
While it is now well established that the CSC component
is the target to aim for treatment, it remains to be deter-
mined whether it is a unique target, and what is the best
way to counteract its potential adaptation to the host envi-
ronment: progression, expansion and response to treat-
ment.
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